Ownership and insider activity for Arvinas, Inc. (ARVN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates.
Price
| Price | $8.16 |
| Market Cap | $526M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-24 | Smaldone Alsup Laurie | A-Award | 15,527 | |
| 2026-06-24 | Smaldone Alsup Laurie | A-Award | 22,714 | $183K |
| 2026-06-24 | Norwalk Leslie V | A-Award | 15,527 | |
| 2026-06-24 | Norwalk Leslie V | A-Award | 22,714 | $183K |
| 2026-06-24 | Morrison Briggs | A-Award | 15,527 | |
| 2026-06-24 | Morrison Briggs | A-Award | 22,714 | $183K |
| 2026-06-24 | Kennedy Edward Moore Jr. | A-Award | 15,527 | |
| 2026-06-24 | Kennedy Edward Moore Jr. | A-Award | 22,714 | $183K |
| 2026-06-24 | Cunningham Everett | A-Award | 15,527 | |
| 2026-06-24 | Cunningham Everett | A-Award | 22,714 | $183K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.1M | $30.9M | $3.2M | $9.2M | $588.4M | $108.3M | $81.3M | $311.7M | $100.5M | $142.9M |
| Short-term Investments | $30.5M | $8.3M | $184.6M | $271.7M | $100.2M | $1.39B | $1.12B | $949.3M | $938.9M | $542.5M |
| Receivables | $1.4M | $26.0M | $5.0M | $6.3M | $8.4M | $25.7M | $8.0M | $7.2M | $13.7M | $6.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $37.3M | $65.5M | $195.7M | $290.9M | $703.1M | $1.55B | $1.24B | $1.28B | $1.07B | $700.7M |
| Property, Plant & Equipment | $633848 | $1.3M | $3.6M | $10.7M | $14.3M | $16.6M | $17.8M | $14.0M | $16.0M | $13.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $37.9M | $66.8M | $199.3M | $301.6M | $717.4M | $1.58B | $1.27B | $1.30B | $1.09B | $717.9M |
| Accounts Payable | $1.6M | $596527 | $2.8M | $4.6M | $7.1M | $31.3M | $5.7M | $17.8M | $13.4M | $24.4M |
| Short-term Debt | $141212 | $159265 | $154461 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $10.0M | $17.9M | $23.0M | $32.8M | $49.2M | $261.7M | $295.1M | $257.1M | $229.8M | $142.5M |
| Long-term Debt | $312575 | $151122 | $2.0M | $2.0M | $2.0M | $1.0M | $1.0M | $800000 | $600000 | $400000 |
| Total Liabilities | $13.9M | $66.6M | $62.6M | $75.0M | $75.2M | $799.9M | $703.9M | $644.6M | $529.7M | $284.1M |
| Retained Earnings | -$33.8M | -$62.4M | -$302.3M | -$372.6M | -$491.9M | -$682.9M | -$965.4M | -$1.33B | -$1.53B | -$1.61B |
| Total Equity | $24.0M | $245870 | $136.7M | $226.7M | $642.2M | $781.7M | $564.9M | $660.0M | $561.7M | $433.8M |
| Total Debt | $453787 | $310387 | $2.2M | $4.4M | $4.1M | $5.0M | $5.5M | $3.2M | $9.7M | $8.9M |
| Net Debt | -$35.1M | -$38.9M | -$185.7M | -$276.5M | -$684.5M | -$1.50B | -$1.20B | -$1.26B | -$1.03B | -$676.5M |
| Working Capital | $27.2M | $47.7M | $172.7M | $258.1M | $653.9M | $1.29B | $945.1M | $1.02B | $837.5M | $558.2M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 7.91 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -0.75 |
Profitability
| Return on Equity | 1.91% |
| Return on Invested Capital | -2.18% |
| Return on Assets | 1.38% |
| Gross Margin | 96.43% |
| Operating Margin | -4.45% |
| Net Margin | 2.94% |
Related companies: ATXS · AVBP · DAWN · DNA · ERAS · GERN · IOVA
Explore sector: Healthcare · Biotechnology
More sections of ARVN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks